Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients

Adam J Starr, Zachary Shirley, Patrick D Sutphin, Drew T Sanders, Alexander Eastman, Brigham Au, Ashoke K Sathy, Gene Hu, Aaron Gebrelul, Joseph P Minei, Michael W Cripps

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: To report results of a protocol to lessen incidence of pulmonary embolism (PE) among orthopaedic trauma patients. DESIGN: Retrospective review. SETTING: Level 1 trauma center. PATIENT/PARTICIPANTS: Orthopaedic trauma inpatients were included in the study. INTERVENTION: On arrival, an orthopaedic trauma patient's PE risk is calculated using a previously developed tool. If possible, patients at high risk are given their first dose of enoxaparin before leaving the emergency room. If other injuries preclude enoxaparin, then chemoprophylaxis is held for 24 hours. Twenty-four hours after arrival, the patient's ability to receive enoxaparin is reassessed. If possible, enoxaparin is started, with dosing twice a day. If enoxaparin is still contraindicated, a removable inferior vena cava filter is placed. Adequacy of enoxaparin dosing is tested using anti-factor Xa assay, drawn 4 hours after the third dose of enoxaparin. If the anti-factor Xa result is less than 0.2 IU/mL, a removable inferior vena cava filter is placed. If the result is 0.2-0.5 IU/mL, enoxaparin dosing is continued. If greater than 0.5 IU/mL, the dose of enoxaparin is reduced. OUTCOME MEASURE: The main outcome measure was rate of PE. RESULTS: From September 1, 2015 to December 31, 2015, our hospital admitted 420 orthopaedic trauma patients. Fifty-one patients were classed as high risk for PE. In September through December 2015, 9 sustained PE, 1 of which was fatal. From September 1, 2016 to December 31, 2016, our hospital admitted 368 orthopaedic trauma patients with comparable age and Injury Severity Score to 2015. Forty patients were at high risk for PE, 1 sustained a nonfatal PE. PE incidence from September to December 2016 was significantly lower than in 2015 (P = 0.02). Overall, 26 patients managed under the new protocol had IVCFs placed, 21 had their filters removed, and 3 died with filters in place. There were no complications during filter placement or removal. One patient had hemorrhage felt to be attributable to enoxaparin. CONCLUSIONS: Our protocol emphasizes more robust enoxaparin dosing, and more frequent use of IVCF, but only among those at high risk. We lessened the incidence of PE, with a low complication rate. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

Original languageEnglish (US)
Pages (from-to)78-81
Number of pages4
JournalJournal of orthopaedic trauma
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Enoxaparin
Pulmonary Embolism
Orthopedics
Wounds and Injuries
Vena Cava Filters
Factor Xa
Incidence
Injury Severity Score
Trauma Centers
Chemoprevention
Hospital Emergency Service
Inpatients
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients. / Starr, Adam J; Shirley, Zachary; Sutphin, Patrick D; Sanders, Drew T; Eastman, Alexander; Au, Brigham; Sathy, Ashoke K; Hu, Gene; Gebrelul, Aaron; Minei, Joseph P; Cripps, Michael W.

In: Journal of orthopaedic trauma, Vol. 33, No. 2, 01.02.2019, p. 78-81.

Research output: Contribution to journalArticle

Starr, Adam J ; Shirley, Zachary ; Sutphin, Patrick D ; Sanders, Drew T ; Eastman, Alexander ; Au, Brigham ; Sathy, Ashoke K ; Hu, Gene ; Gebrelul, Aaron ; Minei, Joseph P ; Cripps, Michael W. / Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients. In: Journal of orthopaedic trauma. 2019 ; Vol. 33, No. 2. pp. 78-81.
@article{c23f11f804884ea28f4d51fa46fe5db6,
title = "Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients",
abstract = "OBJECTIVES: To report results of a protocol to lessen incidence of pulmonary embolism (PE) among orthopaedic trauma patients. DESIGN: Retrospective review. SETTING: Level 1 trauma center. PATIENT/PARTICIPANTS: Orthopaedic trauma inpatients were included in the study. INTERVENTION: On arrival, an orthopaedic trauma patient's PE risk is calculated using a previously developed tool. If possible, patients at high risk are given their first dose of enoxaparin before leaving the emergency room. If other injuries preclude enoxaparin, then chemoprophylaxis is held for 24 hours. Twenty-four hours after arrival, the patient's ability to receive enoxaparin is reassessed. If possible, enoxaparin is started, with dosing twice a day. If enoxaparin is still contraindicated, a removable inferior vena cava filter is placed. Adequacy of enoxaparin dosing is tested using anti-factor Xa assay, drawn 4 hours after the third dose of enoxaparin. If the anti-factor Xa result is less than 0.2 IU/mL, a removable inferior vena cava filter is placed. If the result is 0.2-0.5 IU/mL, enoxaparin dosing is continued. If greater than 0.5 IU/mL, the dose of enoxaparin is reduced. OUTCOME MEASURE: The main outcome measure was rate of PE. RESULTS: From September 1, 2015 to December 31, 2015, our hospital admitted 420 orthopaedic trauma patients. Fifty-one patients were classed as high risk for PE. In September through December 2015, 9 sustained PE, 1 of which was fatal. From September 1, 2016 to December 31, 2016, our hospital admitted 368 orthopaedic trauma patients with comparable age and Injury Severity Score to 2015. Forty patients were at high risk for PE, 1 sustained a nonfatal PE. PE incidence from September to December 2016 was significantly lower than in 2015 (P = 0.02). Overall, 26 patients managed under the new protocol had IVCFs placed, 21 had their filters removed, and 3 died with filters in place. There were no complications during filter placement or removal. One patient had hemorrhage felt to be attributable to enoxaparin. CONCLUSIONS: Our protocol emphasizes more robust enoxaparin dosing, and more frequent use of IVCF, but only among those at high risk. We lessened the incidence of PE, with a low complication rate. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.",
author = "Starr, {Adam J} and Zachary Shirley and Sutphin, {Patrick D} and Sanders, {Drew T} and Alexander Eastman and Brigham Au and Sathy, {Ashoke K} and Gene Hu and Aaron Gebrelul and Minei, {Joseph P} and Cripps, {Michael W}",
year = "2019",
month = "2",
day = "1",
doi = "10.1097/BOT.0000000000001346",
language = "English (US)",
volume = "33",
pages = "78--81",
journal = "Journal of Orthopaedic Trauma",
issn = "0890-5339",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients

AU - Starr, Adam J

AU - Shirley, Zachary

AU - Sutphin, Patrick D

AU - Sanders, Drew T

AU - Eastman, Alexander

AU - Au, Brigham

AU - Sathy, Ashoke K

AU - Hu, Gene

AU - Gebrelul, Aaron

AU - Minei, Joseph P

AU - Cripps, Michael W

PY - 2019/2/1

Y1 - 2019/2/1

N2 - OBJECTIVES: To report results of a protocol to lessen incidence of pulmonary embolism (PE) among orthopaedic trauma patients. DESIGN: Retrospective review. SETTING: Level 1 trauma center. PATIENT/PARTICIPANTS: Orthopaedic trauma inpatients were included in the study. INTERVENTION: On arrival, an orthopaedic trauma patient's PE risk is calculated using a previously developed tool. If possible, patients at high risk are given their first dose of enoxaparin before leaving the emergency room. If other injuries preclude enoxaparin, then chemoprophylaxis is held for 24 hours. Twenty-four hours after arrival, the patient's ability to receive enoxaparin is reassessed. If possible, enoxaparin is started, with dosing twice a day. If enoxaparin is still contraindicated, a removable inferior vena cava filter is placed. Adequacy of enoxaparin dosing is tested using anti-factor Xa assay, drawn 4 hours after the third dose of enoxaparin. If the anti-factor Xa result is less than 0.2 IU/mL, a removable inferior vena cava filter is placed. If the result is 0.2-0.5 IU/mL, enoxaparin dosing is continued. If greater than 0.5 IU/mL, the dose of enoxaparin is reduced. OUTCOME MEASURE: The main outcome measure was rate of PE. RESULTS: From September 1, 2015 to December 31, 2015, our hospital admitted 420 orthopaedic trauma patients. Fifty-one patients were classed as high risk for PE. In September through December 2015, 9 sustained PE, 1 of which was fatal. From September 1, 2016 to December 31, 2016, our hospital admitted 368 orthopaedic trauma patients with comparable age and Injury Severity Score to 2015. Forty patients were at high risk for PE, 1 sustained a nonfatal PE. PE incidence from September to December 2016 was significantly lower than in 2015 (P = 0.02). Overall, 26 patients managed under the new protocol had IVCFs placed, 21 had their filters removed, and 3 died with filters in place. There were no complications during filter placement or removal. One patient had hemorrhage felt to be attributable to enoxaparin. CONCLUSIONS: Our protocol emphasizes more robust enoxaparin dosing, and more frequent use of IVCF, but only among those at high risk. We lessened the incidence of PE, with a low complication rate. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

AB - OBJECTIVES: To report results of a protocol to lessen incidence of pulmonary embolism (PE) among orthopaedic trauma patients. DESIGN: Retrospective review. SETTING: Level 1 trauma center. PATIENT/PARTICIPANTS: Orthopaedic trauma inpatients were included in the study. INTERVENTION: On arrival, an orthopaedic trauma patient's PE risk is calculated using a previously developed tool. If possible, patients at high risk are given their first dose of enoxaparin before leaving the emergency room. If other injuries preclude enoxaparin, then chemoprophylaxis is held for 24 hours. Twenty-four hours after arrival, the patient's ability to receive enoxaparin is reassessed. If possible, enoxaparin is started, with dosing twice a day. If enoxaparin is still contraindicated, a removable inferior vena cava filter is placed. Adequacy of enoxaparin dosing is tested using anti-factor Xa assay, drawn 4 hours after the third dose of enoxaparin. If the anti-factor Xa result is less than 0.2 IU/mL, a removable inferior vena cava filter is placed. If the result is 0.2-0.5 IU/mL, enoxaparin dosing is continued. If greater than 0.5 IU/mL, the dose of enoxaparin is reduced. OUTCOME MEASURE: The main outcome measure was rate of PE. RESULTS: From September 1, 2015 to December 31, 2015, our hospital admitted 420 orthopaedic trauma patients. Fifty-one patients were classed as high risk for PE. In September through December 2015, 9 sustained PE, 1 of which was fatal. From September 1, 2016 to December 31, 2016, our hospital admitted 368 orthopaedic trauma patients with comparable age and Injury Severity Score to 2015. Forty patients were at high risk for PE, 1 sustained a nonfatal PE. PE incidence from September to December 2016 was significantly lower than in 2015 (P = 0.02). Overall, 26 patients managed under the new protocol had IVCFs placed, 21 had their filters removed, and 3 died with filters in place. There were no complications during filter placement or removal. One patient had hemorrhage felt to be attributable to enoxaparin. CONCLUSIONS: Our protocol emphasizes more robust enoxaparin dosing, and more frequent use of IVCF, but only among those at high risk. We lessened the incidence of PE, with a low complication rate. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

UR - http://www.scopus.com/inward/record.url?scp=85060626760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060626760&partnerID=8YFLogxK

U2 - 10.1097/BOT.0000000000001346

DO - 10.1097/BOT.0000000000001346

M3 - Article

C2 - 30489428

AN - SCOPUS:85060626760

VL - 33

SP - 78

EP - 81

JO - Journal of Orthopaedic Trauma

JF - Journal of Orthopaedic Trauma

SN - 0890-5339

IS - 2

ER -